Tecentriq 1 200 mg concentrate for solution for infusion, LURBINECTEDIN, RO7508182
GO43104
Phase 3 small_molecule active
Quick answer
Tecentriq 1 200 mg concentrate for solution for infusion, LURBINECTEDIN, RO7508182 for Small-Cell Lung Cancer (SCLC) is a Phase 3 program (small_molecule) at Roche Registration Limited with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Roche Registration Limited
- Indication
- Small-Cell Lung Cancer (SCLC)
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active